Results 1 to 10 of about 7,744 (130)

Pomalidomide-induced acute eosinophilic pneumonia: a case report [PDF]

BMC Pulmonary Medicine
Eosinophilic pneumonia secondary to drug exposure is a recognized but infrequent complication associated with a variety of medications, including oncological therapies.
Mathieu Megevet, Jessica Freitas Pereira, Jeanne Vervier, Pierre-Yves Lovey, Vincent Soubeyran, Pierre-Olivier Bridevaux   +5 more
doaj   +2 more sources

Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report [PDF]

Annals of Hematology
Pomalidomide, an analogue of lenalidomide and thalidomide, has shown significant activity in treating relapsed refractory multiple myeloma (MM). Due to its oral formulation and favorable safety profile, pomalidomide is generally well tolerated, even ...
Francesca Bartolomei, Tommaso Za, Francesca Di Landro, Valerio De Stefano, Elena Rossi   +4 more
doaj   +2 more sources

Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients [PDF]

Journal of Translational Medicine
Background To explore the effect and mechanism of pomalidomide on the immune activity of dendritic cell-derived exosomes (DEXs) from patients with multiple myeloma (MM).
Hu Zhang, Yifan Wang, Xueqing Wang, Hailing Duan, Duonan Yu, Xiaochuan Kuang, Lin He, Wenyi Zhang, Jie Chen, Jingying Dai   +9 more
doaj   +2 more sources

Pomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS) [PDF]

Blood Advances
: Hereditary hemorrhagic telangiectasia (HHT) causes severe recurrent epistaxis, chronic gastrointestinal bleeding, solid organ arteriovenous malformations, and significant anemia.
Ellen Zhang, Raj S. Kasthuri, Joseph Parambil, Vikas Prasad, Vivek N. Iyer, Kevin J. Whitehead, Pamela G. Hodges, Allyson M. Pishko, Miles B. Conrad, Darcy Phelan, Josanna Rodriguez-Lopez, Keith R. McCrae, Hanny Al-Samkari   +12 more
doaj   +2 more sources

Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies [PDF]

Cancer Immunology, Immunotherapy
Background Chimeric antigen receptor T cell (CAR-T) therapy achieves high remission rates in lymphoid malignancies, but its long-term efficacy is limited by poor persistence and T cell exhaustion.
Yi Zhou, Yan Yu, Linzhi Xie, Liwen Wang, Yuhan Yan, Qian Cheng, Jing Liu, Chang Zhang, Xin Li   +8 more
doaj   +2 more sources

Population pharmacokinetics of pomalidomide [PDF]

Journal of Clinical Pharmacology, 2015
AbstractA population pharmacokinetic (PPK) model of pomalidomide was developed and the influence of demographic and disease‐related covariates on PPK parameters was assessed based on data from 6 clinical trials of pomalidomide (dose range, 0.5–10 mg) in healthy participants (n = 96) and patients with multiple myeloma (MM; n = 144).
Maria Palmisano, Simon Zhou
exaly   +3 more sources

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

eJHaem, 2023
Pomalidomide‐dexamethasone (Pd) has been a standard care treatment for relapsed and refractory multiple myeloma since 2013. However, the outcomes of Pd after exposure to CD38 antibodies are not known.
Agoston Gyula Szabo, Jonathan Thorsen, Katrine Fladeland Iversen, Mette Bøegh Levring, Carsten Helleberg, Emil Hermansen, Søren Thorgaard Bønløkke, Katrine Nielsen, Elena Manuela Teodorescu, Eva Kurt, Casper Nørgaard Strandholdt, Annette Juul Vangsted   +11 more
doaj   +1 more source

Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients

Frontiers in Pharmacology, 2022
Objective: To explore the effect of pomalidomide on the maturation of monocyte-derived dendritic cells (moDCs) from healthy donors (HDs) and multiple myeloma (MM) patients.Methods: MoDCs were generated by the incubation of monocytes from peripheral blood
Xi Wang, Jingying Dai, Jingyi Xia, Zichen Ye, Xiaobing Huang, Wanjun Cao, Rong Xiao, Lin He   +7 more
doaj   +1 more source

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma

Therapeutic Advances in Hematology, 2022
Pomalidomide is a potent immunomodulatory agent that is currently a standard of care backbone for the treatment of multiple myeloma (MM) patients in the relapsed/refractory setting after exposure to lenalidomide and a proteasome inhibitor.
Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos   +3 more
doaj   +1 more source

Development and Validation of Pomalidomide Determination in Human Plasma by HPLC-MS/MS Method

Разработка и регистрация лекарственных средств, 2020
Introduction. B-cell malignancies of the plasma cell leads to the second most spread hematological malignancy disease, called multiple myeloma. Pomalidomide is used in case of previous multiple myeloma ineffective treatment. Pomalidomide is a thalidomide
T. N. Komarov, I. E. Shohin, M. A. Tokareva, O. A. Archakova, D. S. Bogdanova, A. A. Aleshina, N. S. Bagaeva, V. V. Davydanova, N. P. Sadchikova   +8 more
doaj   +1 more source